In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Drug Controller Trapped In Crossfire Of Rival Lobbying Groups

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Deep fissures within the Indian drug industry may surface soon over regulatory reforms initiated by Drug Controller General of India Surinder Singh

You may also be interested in...



Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism

MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh

Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism

MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh

Drug Controller General Of India Surinder Singh On India’s Regulatory Overhaul: An Interview With PharmAsia News

Surinder Singh took the mantle of the Drug Controller General of India a few months ago. From being a microbiologist to handling the most important regulatory position in the Indian drug industry, Singh is already confronted with a host of challenges. Overhauling the regulatory system, dealing with vexatious registration issues and advocating for Indian drug industry on global forums, Singh has been working on an extremely tight schedule. Singh took time off from his busy routine and sat down with PharmAsia News' India bureau to discuss India's impending regulatory overhaul (PharmAsia News, Sept. 11, 2008).

Related Content

UsernamePublicRestriction

Register

SC075216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel